Aquestive Therapeutics (NASDAQ:AQST) Insider Sherry Korczynski Sells 15,741 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Sherry Korczynski sold 15,741 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total transaction of $65,639.97. Following the completion of the sale, the insider directly owned 241,117 shares of the company’s stock, valued at $1,005,457.89. The trade was a 6.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Aquestive Therapeutics Price Performance

NASDAQ AQST traded down $0.18 on Thursday, hitting $4.09. 574,749 shares of the company were exchanged, compared to its average volume of 5,516,916. The company’s 50 day moving average price is $4.08 and its 200-day moving average price is $5.21. Aquestive Therapeutics, Inc. has a twelve month low of $2.12 and a twelve month high of $7.55. The firm has a market capitalization of $498.66 million, a P/E ratio of -5.28 and a beta of 1.61.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The business had revenue of $13.02 million during the quarter, compared to the consensus estimate of $13.28 million. As a group, equities analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Victory Capital Management Inc. lifted its stake in shares of Aquestive Therapeutics by 17.0% in the third quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock valued at $72,000 after buying an additional 1,862 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Aquestive Therapeutics by 6.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock valued at $156,000 after acquiring an additional 2,649 shares during the period. Informed Momentum Co LLC increased its stake in Aquestive Therapeutics by 1.8% during the fourth quarter. Informed Momentum Co LLC now owns 155,053 shares of the company’s stock valued at $1,002,000 after acquiring an additional 2,721 shares during the period. Stifel Financial Corp raised its stake in shares of Aquestive Therapeutics by 0.9% in the fourth quarter. Stifel Financial Corp now owns 369,728 shares of the company’s stock valued at $2,388,000 after purchasing an additional 3,300 shares in the last quarter. Finally, AQR Capital Management LLC increased its holdings in Aquestive Therapeutics by 6.8% in the 4th quarter. AQR Capital Management LLC now owns 61,709 shares of the company’s stock valued at $399,000 after buying an additional 3,934 shares during the period. Institutional investors and hedge funds own 32.45% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on AQST. Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a research note on Tuesday, February 3rd. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $8.80.

Key Stories Impacting Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright raised several near?term EPS estimates and lifted its FY2026 view (less negative) — modest analytical support for the story and potential relief if guidance/progress continues. HC Wainwright Estimates
• Positive Sentiment: Independent coverage remains constructive on Anaphylm: a Seeking Alpha piece reiterates a Buy and argues the CRL issues are addressable (packaging/labeling), forecasting a high approval/adoption probability if the planned PK study succeeds. That supports upside tied to regulatory progress. Seeking Alpha: Anaphylm
• Neutral Sentiment: Short?interest data in feeds is currently reporting anomalous/zero values (likely data error) and should not be relied on for a short?squeeze narrative until official reporting clears up. (No reliable link.)
• Negative Sentiment: Multiple law firms and notice filings indicate a securities class action has been filed and several firms are soliciting lead?plaintiff roles for purchasers from June 16, 2025 to Jan 8, 2026 — this increases legal exposure, potential costs, and investor uncertainty. Representative notices: Bernstein Liebhard, Rosen, Portnoy/others. Bernstein Liebhard Alert Portnoy Notice
• Negative Sentiment: A PRNewswire item highlights a lawsuit alleging an analyst (Cantor) slashed AQST’s price target from $15 to $8 (Jan 9), linking that cut to a >37% one?day loss for certain holders — adds a contested narrative about analyst conduct and market impact. PR Newswire: Analyst Lawsuit
• Negative Sentiment: Large insider sales were disclosed on March 10 (CEO and multiple senior officers sold sizeable blocks at ~ $4.17), reducing insider ownership materially — often interpreted by markets as a negative signal about near?term prospects or liquidity needs. Representative SEC filing (CEO): SEC Filing (CEO Sale)

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.